BioSpace News Archive

Allakos Inc. today announced a restructuring to reduce costs and to focus on AK006 clinical development and additional preclinical programs. As a result, the Company’s cash runway is expected to extend into mid-2026.

Ecovyst Inc. today announced that Kara L. Thornton has been appointed Vice President and Chief Human Resources Officer.

In a first-in-human study, researchers at Orlucent, Inc. have demonstrated the viability of a novel handheld point-of-care molecular Skin Fluorescence Imaging (mSFI) System to noninvasively identify and clinically assess the presence of biological tissue remodeling activity associated with the development of melanoma in adults.

Neurogene Inc. today announced the appointment of Julie Jordan, M.D., as Chief Medical Officer.

Accurus Biosciences Inc. (“Accurus”) is pleased to announce that it has entered into a worldwide licensing agreement for its CLDN18.2 monoclonal antibody with ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a clinical-stage company focusing on the development of next generation chimeric antigen receptor (CAR) T-cell therapies.

Aviceda Therapeutics announced today positive topline data of Part 1 of the Phase 2/3 SIGLEC trial for AVD-104 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), showing positive safety and efficacy outcomes which were observed at 3 months after a single dose of AVD-104.

Anavex Life Sciences Corp. today announced the initiation of the U.S. FDA cleared placebo-controlled Phase 2 trial of ANAVEX®3-71 for the treatment of schizophrenia, which is expected to begin in Q2 2024. ANAVEX®3-71 positive initial Phase 1 results in healthy volunteers were previously reported.

Bexion Pharmaceuticals, Inc. today announced a Trials in Progress poster presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), being held January 18-20, 2024, in San Francisco, CA.

Daxor Corporation announces it will be exhibiting at the Society for Critical Care Medicine 2024 Critical Care Congress at the Phoenix Convention Center in Phoenix, AZ from January 21 through January 23, 2024.

Integer Holdings Corporation, a leading medical device outsource manufacturer, will join medtech leaders and innovators around the world in exhibiting at the North American Neuromodulation Society Annual Meeting at Caesars Palace in Las Vegas from Jan. 18 – 21, 2024.